Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STRO-004 |
| Synonyms | |
| Therapy Description |
STRO-004 is an antibody-drug conjugate (ADC) targeting F3 (TF) with a DAR8 beta-glucoronidase linker and exatecan payload, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1572). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STRO-004 | STRO004|STRO 004 | STRO-004 is an antibody-drug conjugate (ADC) targeting F3 (TF) with a DAR8 beta-glucoronidase linker and exatecan payload, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1572). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07227168 | Phase I | Pembrolizumab + STRO-004 STRO-004 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Recruiting | USA | 0 |